not tagged
daiichi sankyo
['nsclc', 'sclc', 'crpc', 'daiichi']
#esmo22 news: our investigational b7-h3 directed #adc developed with continues to show promising durable tumor response in patients with #sclc #nsclc #crpc and #escc. learn more about the phase 1/2 data presented: 
We create life-changing solutions for patients. See our guidelines: https://t.co/4iEAbpw1Wx